StockData

Electromed vs Iridex

ELMD and IRIX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELMD and IRIX compare

Electromed is the larger company, worth 17 times as much as Iridex ($203M against $12.1M).

Electromed grew revenue faster over the last twelve months (14.1% versus 3.7% for Iridex).

Electromed keeps more of each dollar of sales as profit, with a net margin of 15.8% compared with −6.9% at Iridex.

Electromed scores higher on the StockData Score (21 against 8 for Iridex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELMDIRIX
Size and price
Market cap$203M$12.1M
Share price$24.32$0.690
Change, 1 year−4.2%−27.7%
Change, 5 years106%−91.0%
Beta (5Y)0.490.93
Employees19793
StockData Score
Total score21 (better)8
Valuation score5 (better)1
Growth score5 (better)0
Performance score5 (better)2
Health score6 (better)5
Dividend score00
Valuation
P/E17.6×–
P/S2.7×0.2× (better)
P/B3.9×3.3× (better)
EV/EBITDA12.8×–
P/FCF23.4×–
PEG0.33–
FCF yield4.3% (better)−16.5%
Fair value$33.69–
Margin of safety27.8%–
Growth
Revenue growth (TTM)14.1% (better)3.7%
Revenue growth, 5Y average15.6% (better)7.7%
Net income growth (TTM)45.5%–
EPS growth (TTM)48.4%–
EPS growth, 5Y average36.9%–
Profitability
Gross margin79.0% (better)35.9%
Operating margin19.5% (better)−5.4%
Net margin15.8% (better)−6.9%
FCF margin11.5% (better)−3.9%
Return on equity24.5% (better)−73.1%
Return on invested capital34.3%–
Financial health
Debt / equity0.000.00
Current ratio7.19 (better)1.82
Altman Z-score17.69 (better)−2.50
Piotroski F-score8 (better)5
Dividends and buybacks
Buyback yield3.6%–
Shareholder yield3.6% (better)0.00%
Ownership
Held by institutions55.6%12.4%
Held by insiders11.4%76.1%
Insider net buying, 12 months−$2.2M$536K (better)
Short interest, % of float2.4%0.94%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.